Compare Tenaris S.A. American Depositary Shares (TS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenaris S.A. American Depositary Shares vs Zimmer Biomet Holdings Inc — how do they compare? Tenaris S.A. American Depositary Shares trades at $58.11 (market cap $29.31B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.56B). The key difference: Tenaris S.A. American Depositary Shares is the larger of the two by market cap, and Tenaris S.A. American Depositary Shares pays the higher dividend (4.07%). Which is the better fit depends on your goals — on Pluang, investors hold Tenaris S.A. American Depositary Shares for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TS | ZBH | |
|---|---|---|
Market Cap | $29.31B | $17.56B |
Volume | 802,043 | 2,298,426 |
Sector | Energy | Health |
52-Week High | $64.02 | $103.98 |
52-Week Low | $34.28 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $26.97B | $24.63B |
Dividend Yield | 4.07% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Zimmer Biomet (ZBH) trades at $91.77, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady at $8.23B for 2025, though net income margins have moderated from 13.84% in 2023 to 8.56% in 2025. The company maintains strong profitability with a 69.87% gross margin and recently announced a $0.24 quarterly dividend.
ZBH presents a mixed outlook with positive earnings momentum and analyst consensus price target of $103.11 offering 12% upside potential. However, rising debt levels and competitive pressures in medical technology pose risks. Institutional ownership trends show continued interest, with State Street increasing its position by 0.6% in Q3 2026. The stock's valuation at 22.35 P/E appears reasonable given the company's market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tenaris S.A. American Depositary Shares
Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
